BeOne Medicines (ONC) Net Income (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Net Income data on file, last reported at $227.4 million in Q1 2026.

• On a quarterly basis, Net Income rose 17802.13% year-over-year to $227.4 million in Q1 2026; TTM through Mar 2026 was $513.0 million, a 230.75% increase from a year earlier, with the FY2025 full-year figure at $286.9 million, up 144.5% from the prior year.
• Net Income for Q1 2026 stood at $227.4 million, up from $66.5 million in the prior quarter.
• Over the last five years, Net Income for ONC reached as high as $227.4 million in Q1 2026 and fell as low as -$565.7 million in Q2 2022.
• Historically, Net Income has averaged -$177.4 million across 5 years, with a median of -$151.9 million in 2024.
• Across the five-year window, Net Income slumped 754.48% in 2022 and soared 17802.13% in 2026, its largest moves.
• Year by year, Net Income stood at -$445.3 million in 2022, then increased by 17.47% to -$367.6 million in 2023, then jumped by 58.68% to -$151.9 million in 2024, then jumped by 143.79% to $66.5 million in 2025, then surged by 241.88% to $227.4 million in 2026.
• Per Business Quant data, the three most recent Net Income figures were $227.4 million in Q1 2026, $66.5 million in Q4 2025, and $124.8 million in Q3 2025.